Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207

Japanese Journal of Cancer Research

Volumn 91, Issue 12, 2000, Pages 1339-1344

  Oyama, Masafumi ^a   Ohigashi, Takashi ^a   Hoshi, Michio ^a,b   Murai, Masaru ^a   Uyemura, Keiichi ^a   Yazaki, Takahito ^a,b  

^a Department of Physiology ^*  (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Gene therapy; Herpes simplex virus; Oncolytic virus; Prostate neoplasms; Replication competent virus

Indexed keywords

BETA GALACTOSIDASE; ONCOLYTIC VIRUS; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CONTROLLED STUDY; GENE THERAPY; GROWTH RATE; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION SENSITIVITY; INOCULATION; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; VIROGENESIS; VIRUS CULTURE; VIRUS PLAQUE; VIRUS REPLICATION;

ANIMALS; CELL DIVISION; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0034524154     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2000.tb00923.x     Document Type: Article

References (20)

1. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207
2. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
3. Cancer statistics, 1999
4. Radical prostatectomy for clinical stage T1-2NOMO prostatic adenocarcinoma: Long-term results
5. Radiation therapy for localized prostate cancer. Justification by long-term follow-up
6. Radical prostatectomy
7. Current status of gene therapy for prostate and bladder cancer
8. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
9. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
10. p53 is mutated in a subset of advanced-stage prostate cancers
11. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture
12. Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage
13. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant
14. Experimental therapy of human glioma by means of a genetically engineered virus mutant
15. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1
16. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207)
17. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1
18. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation in mice
19. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates
20. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice